1,2-二油酰基-SN-甘油-3-琥珀酸 | 127640-49-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 中文名称: 1,2-二油酰基-SN-甘油-3-琥珀酸
• 英文名称: 4-[(2R)-2,3-Bis{[(9Z)-octadec-9-enoyl]oxy}propoxy]-4-oxobutanoic acid
• 英文别名: 4-[(2R)-2,3-bis[[(Z)-octadec-9-enoyl]oxy]propoxy]-4-oxobutanoic acid
• CAS: 127640-49-7
• 化学式: C₄₃H₇₆O₈
• 分子量: 721.1
• InChiKey: VZGIZLLBNVAMQT-NYVOMTAGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.3
• 重原子数：
  51
• 可旋转键数：
  41
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  8

安全信息

• WGK Germany：
  3

文献信息

• Novel colloid synthetic vectors for gene therapy
  申请人：——

  公开号：US20030166601A1

  公开（公告）日：2003-09-04

  Non-naturally occurring vector for gene therapy are provided, comprised of chemically defined reagents, where the vector is self-assembling and where the vector comprises (1) a core complex comprising a nucleic acid and (2) at least one complex forming reagent, where the vector has fusogenic activity. The vector optionally may contain reagents permitting fusion with cell membranes and nuclear uptake. The vector also may contain an outer shell moiety that is anchored to the core complex, whereby the outer shell stabilizes the complex, protects it from unwanted interactions and enhances delivery of the nucleic acid into a target tissue or cell. The outer shell optionally may be sheddable, that is, it may be designed such that it dissociates from the vector upon entry into the target cell or tissue.

  提供了一种非自然发生的基因治疗载体，由化学定义的试剂组成，其中载体是自组装的，包括（1）核酸的核心复合物和（2）至少一个复合物形成试剂，其中载体具有融合活性。该载体可选地包含允许与细胞膜融合和核摄取的试剂。该载体还可以包含一个外壳基团，该基团固定在核心复合物上，从而稳定外壳，保护它免受不必要的相互作用，并增强核酸传递到目标组织或细胞的能力。外壳可选地可脱落，即它可以被设计成在进入目标细胞或组织时与载体分离。
• MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED INTRACELLULAR CARGO DELIVERY
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP3838266A1

  公开（公告）日：2021-06-23

  The present invention relates to a method for preparation of monodisperse cell-targeting giant unilamellar vesicles based on symmetrically division of a parent polymer shell-stabilized giant unilamellar vesicle into smaller polymer shell-stabilized giant unilamellar vesicles with a diameter smaller than 10 µm using a microfluidic splitting device. The inventive method allows preparation of differently charged giant unilamellar vesicles as well as bioligand- and PEG-conjugated giant unilamellar vesicles, which are useful for targeted cellular delivery at high efficiency and specificity. A further advantage of the present invention is that the giant unilamellar vesicles can deliver huge cargos such as drug releasing porous microparticles, high amounts of in vivo imaging probes, viruses, or up-and-coming DNA origami robots.

  本发明涉及一种制备单分散细胞靶向巨型单拉美米尔囊泡的方法，其基础是利用微流体分割装置将母体聚合物壳稳定巨型单拉美米尔囊泡对称分割成直径小于10微米的较小聚合物壳稳定巨型单拉美米尔囊泡。 本发明的方法可制备不同电荷的巨型单拉米分子囊泡以及生物配体和 PEG 共轭巨型单拉米分子囊泡，这些囊泡可用于高效、特异性的细胞靶向递送。本发明的另一个优点是，巨型单拉美拉尔囊泡可以输送巨大的载体，如释放药物的多孔微颗粒、大量的体内成像探针、病毒或新兴的 DNA 折纸机器人。
• BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP3858332A1

  公开（公告）日：2021-08-04

  The present invention relates to a method for producing synthetic extracellular vesicles comprising a lipid bilayer including at least two lipids, optionally one or more extracellular vesicle associated proteins, and optionally one or more nucleic acid molecules. The inventive synthetic extracellular vesicles are formed by emulsification using a mechanic emulsifier in the form of polymer shell stabilized synthetic extracellular vesicles. The inventive method allows producing synthetic extracellular vesicles miming the composition and function of natural extracellular vesicles. Therefore, synthetic extracellular vesicles with specific protein and nucleic acids compositions are also disclosed herein, as well as their therapeutic uses.

  本发明涉及一种生产合成细胞外囊泡的方法，该囊泡包括一个脂质双分子层，其中至少包括两种脂质、一种或多种细胞外囊泡相关蛋白，以及一种或多种核酸分子。本发明的合成细胞外囊泡是通过使用机械乳化剂乳化形成的聚合物壳稳定合成细胞外囊泡。本发明的方法可以生产出模拟天然细胞外囊泡成分和功能的合成细胞外囊泡。因此，本文还公开了具有特定蛋白质和核酸成分的合成细胞外囊泡及其治疗用途。
• Engineered liposomes as cancer-targeted therapeutics
  申请人：Children's Medical Center Corporation

  公开号：US11260132B2

  公开（公告）日：2022-03-01

  The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell).

  本公开提供了脂质体（如癌症靶向脂质体），脂质体表面共轭有配体（如表皮生长因子受体配体和ICAM-1配体）。在一些实施方案中，不同配体的分子比与脂质体靶向细胞（如癌细胞）表面过表达蛋白的相对分子密度（即比值）互补。
• Nanocell drug delivery system
  申请人：Sengupta Shiladitya

  公开号：US20050266067A1

  公开（公告）日：2005-12-01

  Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

  纳米细胞可以连续输送两种具有不同作用模式或不同药代动力学的不同治疗剂。纳米细胞是通过将含有第一种药剂的纳米芯封装在含有第二种药剂的脂质囊泡内而形成的。外层脂质小室中的药剂首先释放，并可能在纳米芯中的药剂释放之前发挥药效。纳米细胞给药系统可配制成药物组合物，用于向癌症、哮喘等炎症性疾病、类风湿性关节炎等自身免疫性疾病、传染性疾病和癫痫等神经系统疾病患者给药。在治疗癌症时，传统的抗肿瘤药物包含在纳米细胞的外层脂质囊泡中，而抗血管生成药物则装载在纳米芯中。这种安排可使抗肿瘤药剂在肿瘤的血液供应被抗血管生成药剂切断之前首先释放并送达肿瘤。